Drugs / Jitongning Tablet
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03932019 | Jun 2019 → Jun 2021 | spondyloarthropathy | Tasly Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Jitongning Tablet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03932019 ↗ |
| Route | Oral | “Jitongning tablet,3tablets,bid,po” NCT03932019 ↗ |